Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

Cancer Letters

Volumn 136, Issue 2, 1999, Pages 203-213

  Zhu, Zhenping ^a   Lu, Dan ^a   Kotanides, Helen ^a   Santiago, Angel ^a   Jimenez, Xenia ^a   Simcox, Tim ^a   Hicklin, Daniel J ^a   Bohlen, Peter ^a   Witte, Larry ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Cancer therapy; Chimeric antibody; Single chain Fv; VEGF KDR Flk 1

Indexed keywords

CHIMERIC ANTIBODY; RECEPTOR ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING, COMPETITIVE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELLS, CULTURED; COS CELLS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOGLOBULIN G; LYMPHOKINES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032962388     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00324-3     Document Type: Article

References (48)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1:1995;27-31.
2. Weinstat-Saslow D., Steeg P.S. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J. 8:1994;401-407.
3. Liotta L.A., Steep P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of negative and positive regulation. Cell. 64:1991;327-336.
4. Fidler I.J, Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
5. Klagsbrun M., D'Amore P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 53:1991;217-239.
6. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
7. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc. Med. 3:1993;244-250.
8. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. Goldberg I.D., Rosen E.M. Regulation of Angiogenesis. 1997;233 Birkhauser Verlag, Basel/Switzerland.
9. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P.H., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
10. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA. 90:1993;7533-7537.
11. Guidi A.J., Abu-Jawdeh G., Tognazzi K., Dvorak H.F., Brown L.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 78:1996;454-460.
12. Abu-Jawdeh G.M., Faix J.D., Niloff J., Tognazzi K., Manseau E., Dvorak H.F, Brown L.F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 74:1996;1105-1115.
13. Denhart B.C., Guidi A.J., Tognazzi K., Dvorak H.F, Brown L.F. Vascular permeability factor (vascular endothelial growth factor) and its receptors in oral and laryngeal squamous cell carcinoma and displasia. Lab. Invest. 77:1997;659-664.
14. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlates with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 17:1997;2811-2814.
15. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53:1993;5822-5827.
16. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London). 367:1994;576-579.
17. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimtrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase receptor as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
18. Kim J., Li B., Winer J., Armanini M., Gillett N., Phillip H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (London). 362:1993;841-844.
19. Rockwell P., Goldstein N. Role of protein tyrosine kinase receptors in cancer: possibilities for therapeutic intervention. Mol. Cell. Differ. 3:1995;315-335.
20. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusening N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1997;1222-1227.
21. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:1996;393-401.
22. Ramakrishnan S., Olson T.A., Bautch V.L., Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 56:1996;1324-1330.
23. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui T.H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirth K.P., Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3545.
24. Rockwell P., Neufeld G., Glassman A., Caron D., Goldstein N. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol. Cell. Differ. 3:1995;91-109.
25. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P, Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single chain antibodies from a phage display library. Cancer Res. 58:1998;3209-3214.
26. D'Angelo G., Struman I., Martial J., Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA. 92:1995;6374-6378.
27. Adams G.P., McCartney J.E., Tai M.S., Oppermann H., Huston J.S., Stafford W.F. III, Bookman M.A., Fand I., Houston L.L, Weiner L.M. High specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erB2 single-chain Fv. Cancer Res. 53:1993;4026-4034.
28. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., Shively J.E, Wu A.M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
29. Neri D., Carnemolla B., Nissim A., Leprini A., Querze G., Balza E., Pini A., Tarli L., Halin C., Neri P., Zardi L., Winter G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol. 15:1997;1271-1274.
30. Witte L., Hicklin D.J., Zhu Z., Pytowski B., Kotanides H., Rockwell P, Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Met. Rev. 17:1998;155-161.
31. Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am. J. Pathol. 143:1993;528-537.
32. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1995;1815-1822.
33. Fan T.-P.D., Jaggar R., Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16:1995;57-66.
34. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell. 7:1994;315-328.
35. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
36. Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
37. Vukanovic J., Passantii A., Hirata T., Traystman R.J., Hartley-Asp B., Issaacs J.T. Antiangiogenesis effects of the quinoline-3-carboxamide linomide. Cancer Res. 53:1994;1833-1837.
38. Yamamoto T., Sudo K., Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res. 14:1994;1-4.
39. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:1994;4082-4085.
40. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
41. Kerbel R.S. A cancer therapy resistant to resistance (News and Views). Nature. 390:1997;335-336.
42. Brekken R.A., Huang X., King S.W., Thorpe P.E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1998;1952-1959.
43. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., Smith L.E.H. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA. 92:1995;905-909.
44. Detmar M., Brown L.F., Claffey K.P., Yeo K-T., Kocher O., Jackman R.W., Berse B., Dvorak H.F. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 180:1994;1141-1146.
45. Wizigmann-Voos S., Bieier G., Risau W., Plate K.H. Up-regulation of vascular endothelial growth factor and its receptor in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55:1995;1358-1364.
46. Koch A.E., Harlow L.A., Haines G.K., Amento E.P., Unemori E.N., Wong W.L., Pope R.M., Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152:1994;4149-4156.
47. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., Noonan D., Salio M., Camussi G., Rockl W., Bussolino F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on endothelial cells. Nat. Med. 2:1996;1371-1375.
48. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of Proteins of Immunological Interest. 5th edn. 1991;National Institutes of Health, Bethesda.